The autophagy process {#Sec1}
=====================

In healthy non-stressed cells, synthesis and degradation of macromolecules (proteins, nucleic acids, lipids, polysaccharides) occur generally at roughly constant levels. Proteins, as major functional macromolecules, are crucial to maintain cellular homeostasis. Therefore, protein synthesis and degradation must be balanced in cells. Any disturbance in this balance may lead to severe dysfunctions of the cell, a group of cells, tissues, organs and the whole organism, as a result of a complex network between various biological processes.

One of two major systems for protein degradation in eukaryotic cells, beside the proteasomal pathway, is the process of lysosome-mediated degradation, called autophagy. This process is phylogenetically old, evolutionarily conserved phenomenon which occurs in all eukaryotic cells. It can be found in yeast *Saccharomyces cerevisiae,* insect *Drosophila melanogaster*, and mammals, including humans. (Ricci and Zong [@CR112]). It is employed mainly to degrade macromolecules in the cytoplasm, particularly proteins of a long half-life, as well as whole organelles, and lysosomes play crucial roles during this degradation (Meijer and Codogno [@CR80]). Randomly selected part of the cytoplasm, together with its compounds, can undergo the digestion, and this kind of the process is called non-selective autophagy. It is employed to maintain the equilibrium in the amount and size of particular components of the cytoplasm. The selective autophagy occurs when special organelles or structures are subjected to degradation, for example mitochondria (the process is called mitophagy), endoplasmic reticulum (reticulophagy), or ribosomes (ribophagy) (Liang and Jung [@CR69]).

The autophagy occurs under physiological conditions (called the basic autophagy), and it is involved in the maintenance of cellular homeostasis. However, it can be stimulated in response to various stress conditions (called the induced autophagy), including oxidative stress (appearance of reactive oxygen species), unfolded proteins, viral infection or starvation. The latter process has a role in the adaptation to new, unfavorable conditions, when the cell is deprived of compounds for the synthesis of new molecules, crucial for survival under stress conditions (Ricci and Zong [@CR112]).

On the basis of the type of delivery of the substrate to lysosomes, three major forms of autophagy have been distinguished: (i) microautophagy, (ii) macroautophagy, and (iii) chaperone-dependent autophagy (Cuervo [@CR15]). Microautophagy is the process devoted to degradation of small organelles and compounds suspended in the cytoplasm (Sakai et al. [@CR117]). In this process, a fragment of cytoplasm is sequestered directly by a lysosome due to invagination of lysosomal membrane (Mijaljica et al. [@CR85]). The chaperone-dependent autophagy involves binding of individual proteins or peptides by chaperones from the Hsp70 family and formation of the chaperone-substrate complexes. Such complexes are transported into lysosomes after being recognized by the receptors Lamp2a (lysosome-associated membrane protein type 2a) and are degraded inside these organelles (Kaushik et al. [@CR48]). Unlike the two mechanisms described above, in which the only organelle necessary to conduct the autophagy process is lysosome, in the case of macroautophagy, a fusion between lysosome and autophagosome is required to degrade selected cellular structures. Macroautophagy is the most common type of autophagy. In the initial step of this process, a fragment of cytoplasm, together with proteins and/or organelles, is engulfed by the phagophore, a double membrane structure. Capturing of the cytoplasm fragment results in formation of autophagosome, to which early and late endosomes can fuse, providing factors required to further fusion with lysosome, as well as factors lowering pH to form acid environment, necessary for activities of lysosomal hydrolases. So prepared autophagosome fuses to lysosome, which leads to formation of the autophagolysosome. Internal membrane of the autophagosome is then degraded, together with organelles and macromolecules included in it. Degradation products (amino acids, nucleotides, simple carbohydrates, fatty acids) are then released to the cytoplasm and can be used in various cellular processes (Dong and Czaja [@CR19]; Ricci and Zong [@CR112]; Cuervo [@CR15]).

The role of autophagy in the cell {#Sec2}
=================================

In eukaryotic cells, the autophagy process has multiple functions. In the normally functioning cell, this process occurs at a constant level, and it is called basic or constitutive autophagy. It is responsible for maintenance of cellular homeostasis by removal of damaged or unnecessary organelles or regulation of the size of endoplasmic reticulum (Qu et al. [@CR104]). Moreover, it facilitates the balance between synthesis and degradation of macromolecules. Basic autophagy is involved also in various physiological processes, like neurolamine synthesis in dopaminergic neurons, surfactant biogenesis in pneumocytes, or erythrocyte maturation (Kim [@CR50]). It also has a role in yeast sporulation, regression of the mammary gland in cattle (Zarzynska and Motyl [@CR169]), and nymph development in *Drosophila melanogaster* (Yang et al. [@CR166]). Autophagy is also necessary for implantation of the mouse embryo into uterus, and its first cellular divisions (Tsukamoto et al. [@CR150]). Mutations in the *Atg*5 gene, coding for a protein responsible for autophagy initiation, result in death of mice shortly after they were born (Kuma et al. [@CR61]). Inactivation of the gene coding for Beclin 1 caused a decrease in life span of *Caenorhabditis elegans* (Meléndez et al. [@CR82]). In contrast, overexpression of the *Atg8* gene, which product is involved in building of the autophagosome membrane, resulted in longer life span of *D. melanogaster* by about 50% (Vellai [@CR153]). It is assumed that this effect depends on one of selective autophagy processes, the mitophagy, in which damaged mitochondria are removed from the cell. This, in turn, restricts the appearance of reactive oxygen species in the cell, and/or facilitates repair of DNA and proteins (Shintani and Klionsky [@CR138]).

The autophagy process is enhanced under conditions of the cellular stress. This process is called the induced autophagy. Among its inductors, there are starvation, a lack of growth factors, viral infection and DNA damage. Under such conditions, the autophagy facilitates adaptation of the cell to new environmental conditions, as it ensures the availability of compounds necessary for synthesis of macromolecules, required during the stress, through degradation of structures that are less important under such conditions. The autophagy is also employed to protect the infected cell from multiplication of viruses or bacteria (Klionsky [@CR56]; Yang et al. [@CR166]). However, long-term and intensive autophagy may lead to cell death, which is called programmed cell death (apoptosis) type II or autophagy-associated apoptosis. This kind of cell death proceeds through condensation of chromatin and degradation of cellular structures, including endoplasmic reticulum, Golgi apparatus, and ribosomes. Contrary to programmed cell death type I (classical apoptosis), the type II of this process is caspase-independent, and requires increased activities of lysosomal enzymes (Qu et al. [@CR104]).

It is worth to note that both over-activity and halting of autophagy can be deleterious for the cell. Inhibition of this process for a longer time may lead to tumorigenesis due to disturbance in cell growth and genome instability (Liu et al. [@CR71]). On the other hand, induction of autophagy in tumor cells can facilitate their survival under hypoxia, deficiency of nutrients, and during chemotherapy.

Molecular mechanism of autophagy {#Sec3}
================================

Molecular mechanism of autophagy has been elucidated for the first time during studies on yeast *S. cerevisiae*. In fact, results of those studies have been recognized as a breakthrough in understanding of cellular processes, and the principal investigator, Yoshinori Ohsumi, has been awarded the Nobel Prize in 2016 (<https://www.nobelprize.org/nobel_prizes/medicine/laureates/2016/press.html>).

Genetic analyses of yeast cells led to identification of 32 genes, coding for proteins taking part in the autophagy process. Such genes are evolutionarily conserved, from yeast to mammals. Therefore, it was proposed to use a common nomenclature of the autophagy genes, consisting of the atg abbreviation (after AuTophaGy-related genes), followed by a consecutive number. Generally, the autophagy process depends on a cascade of interactions between Atg proteins (Kost et al. [@CR59]).

The macroautophagy process (called „autophagy" further in the text) can be divided into 4 stages: (i) initiation, consisting of the synthesis of the isolating membrane, called phagophore, (ii) nucleation and elongation of the isolating membrane, which subsequently closes up, forming the autophagosome structure, (iii) fusion of the autophagosome with lysosomal membrane, which leads to formation of the autophagolysosome, (iv) degradation of the autophagolysosome content, together with its internal membrane, by lysosomal enzymes (Wong et al. [@CR163]). Below, these stages are described in more detail.

Initiation {#Sec4}
----------

Up to now, it is not clear what is the origin of the isolating membrane (phagophore), which is a prerequisite of the autophagosome. There are two hypotheses which may explain this process. The first hypothesis suggests that the membrane may be a part of endoplasmic reticulum or Golgi apparatus (Yorimitsu and Klionsky [@CR168]). According to the second hypothesis, the phagophore is synthesized in the cytoplasm *de novo* (Yang et al. [@CR166]). Most researchers working on the autophagy support the former hypothesis because the transmembrane protein Atg9 is localized in membranes of the late endosomes and in the trans vesicles of the Golgi apparatus. During starvation, Atg9 circulates between Golgi apparatus or late endosomes and newly formatted isolation membrane, providing compounds necessary for autophagosome creation (Yang et al. [@CR167]). The Atg9 protein is present in the phagophore, but it could not be detected on the surface of already formed autophagosomes (Kost et al. [@CR59]). This is caused by removal of this protein from the membrane by the Atg1 protein, which is a serine-threonine kinase, a component of the Atg1-Atg13-Atg17 complex. Formation of this complex depends on the level of Atg13 phosphorylation in which the complex 1 of TOR-TORC1 kinase (target of rapamycin complex 1) is involved. Inactivation of the TOR kinase complex leads to dephosphorylation of Atg13, causing an increase of its affinity to Atg1 and Atg17 and induction of the isolating membrane formation (Yang et al. [@CR167]). The equivalent of the yeast Atg1-Atg13Atg17 complex is mammalian complex composed of the serine-threonine kinase ULK1/2 (Unc51-like kinase 1), a homologue of Atg1, the mAtg13 protein (mammalian Atg13), and FIP200, a mammalian homologue of Atg17 which stabilizes expression of and phosphorylates ULK1/2 (Hara et al. [@CR32]).

To maintain stability and phosphorylation of the ULK1/2 kinase and mAtg, the presence of the Atg101 protein in the phagophore is necessary (Hosokawa et al. [@CR39]; Mercer et al. [@CR84]). In mammalian cells, the autophagy induction depends on the activity of the complex 1 of mTOR kinase (mammalian target of rapamycin). Under physiological conditions, the mTORC1 complex, bound to the ULK1/2-mAtg13-FIP200 complex, is active and phosphorylates the S6K1 kinase. The mAtg13 protein is kept in the hypophosphorylated form, which results in its low affinity to the ULK1/2 kinase. Under starvation conditions or in the deficiency of growth factors, the mTORC1 complex is inactivated and dissociates from the above mentioned complex. This leads to the dephosphorylation of mAtg13 and subsequent activation of ULK1/2 which phosphorylates FIP200 and mAtg13. As a result, the autophagosome membrane formation is initiated (Jung et al. [@CR46]; Mehrpour et al. [@CR79]; Nakatogawa et al. [@CR92]; Yang et al. [@CR167]).

Nucleation and elongation {#Sec5}
-------------------------

At the early stage of the isolating membrane formation, i.e. during nucleation, the presence of the specific complex is required; this complex consists of class III phosphatidil-inositol kinase PI3K (a homologue of the yeast Vps34; vacuolar protein sorting 34), Beclin 1 (Atg6 in yeast), and serine kinase p150 (Vsp15 in yeast) (Kost et al. [@CR59]). The involvement of PI3K in autophagy consists in its crucial role in phagophore elongation, as shown in mammalian cells (Yang et al. [@CR166]; Yorimitsu and Klionsky [@CR168]). The PI3K-Beclin 1-p150 complex, whose core is located in the phagophore, has an enzymatic activity causing production of phosphatidilinositole triphosphate (PIP3) that is indispensable at the stage of phagophore elongation and recruitment of next proteins from the Atg family (Kost et al. [@CR59]). The complex activity, and production of PIP3, is strictly regulated by a battery of other proteins. The UVRAG (UV irradiation resistance-associated tumor suppressor gene) protein, a homologue of yeast Vsp38, is a positive regulator of the autophagosome maturation as it stimulates kinase activity of PI3K (Wong et al. [@CR163]). On the other hand, proteins from the Bcl-2 family (B-cell leukemia/lymphoma-2) and the protein Ambra1 (activating molecule in Beclin1-regulated autophagy) are negative regulators. They bind Beclin 1 and block interactions with PI3K and formation of the complex (Fimia et al. [@CR20]; Zhong et al. [@CR178]; Wong et al. [@CR163]).

In the next step of the isolating membrane elongation, there are two conjugation processes which require the involvement of two protein complexes. The first one is Atg5-Atg12-Atg16L, which requires Atg7 and Atg10 for its formation. Atg12 has to be activated by ATP-dependent formation of thioester bond with Atg7, to form an intermediate complex. Then, it is transferred to Atg10, also forming a thioester bond, and finally it is conjugated with Atg5 through an amide bond. This bond appears to be un-reversible, as no protease able to cut the Atg12-Atg5 complex could be found (Yang et al. [@CR166]; Mariňo and López-Otín [@CR77]).

At the later step, the Atg16L protein is attached to the Atg12-Atg5 protein, forming a covalent bond with Atg5. The Atg12-Atg5-Atg16L complex oligomerizes, forming structures that are used during elongation of the isolating membrane, which results in appearance of the pre-autophagosomal membrane (Yang and Klionsky [@CR165]). It is possible that attachment of the complex may cause the membrane curvature. Initially, the proteins are attached uniformly on the membrane when it is being formed, however, as the phagophore is being elongated, they move towards its outer surface and then they dissociate when the autophagosome is complete. The second complex of proteins taking part in the synthesis of the autophagosomal membrane is Atg8-PE. Apart from Atg8 and phosphatidylethanolamine (PE), Atg3, Atg4 and Atg7 proteins participate in its formation. Activation of the Atg8 protein is initiated due to removal of the C-terminal amino acid, alanine, by the cysteine protease Atg4. This allows to form a thioester bond between Atg8 and Atg7 proteins. The Atg8 protein is transferred on the Atg3 protein, forming another thioester bond. Finally, the Atg8 protein forms a complex with PE through amide bond, thus, PE can be incorporated into the outer membrane of the autophagosome. This bond is reversible, contrary to the bond in the Atg12-Atg5 complex. After the fusion of autophagosome with lysosome, the amide bond is hydrolyzed by the Atg4 protease, and Atg8 dissociates into the cytoplasm (Mariňo and López-Otín [@CR77]).

In mammalian cells, MAP1-LC3 is an equivalent of the yeast Atg8 protein. It was initially considered as a microtubule-associated protein (microtubule associated protein 1 light chain 3). This protein occurs in the cell in 3 forms: (i) pro-LC3, (ii) LC3-I, and (iii) LC3-II. During post-translational modification, pro-LC3 is transformed into LC3-I due to removal of 22 C-terminal amino acids by a mammalian homologue of the yeast Apg4 protease (Kirisako et al. [@CR55]). The LC3-I protein remains in the cytoplasm, with exposed C-terminal glycine, until autophagy is initiated. Then, Atg7 and Atg3 proteins are attached through the C-terminal glycine, and subsequent attachment of the Atg12-Atg5-Atg16L complex results in incorporation of PE and creation of the LC3-II form (Reggiori and Klionsky [@CR109]; Høyer-Hansen and Jäättelä [@CR41]). LC3-II binds to both outer and inner membrane of the forming autophagosome (Yang et al. [@CR166]; Kondo et al. [@CR58]). This protein is released from PE to cytoplasm in the LC3-I form only after the fusion of the mature autophagosome with lysosome. A fraction of LC3-II bound with the inner membrane of autophagolysosome is degraded by lysosomal enzymes (Tanida et al. [@CR147]). These processes cause formation of the autophagosome from the isolating membrane (phagophore), the structure containing a fragment of the cytoplasm together with some proteins and organelles. LC3-II is the only protein which binds specifically to the isolating membrane, autophagosome and autophagolysosome (Yang et al. [@CR166]; Hayashi-Nishino et al. [@CR34]; Carew et al. [@CR11]). Conversion of LC3-I to LC3-II correlates with formation of autophagosome in the cell. In fact, the level of LC3-II is strictly correlated to number of autophagosomes in the cell, thus, it is the only known marker of the autophagy process (Tanida [@CR146]; Sirdharan et al. [@CR139]; Kost et al. [@CR59]).

Fusion of autophagosome with lysosome {#Sec6}
-------------------------------------

After formation of the autophagosome, the outer membrane of autophagosome and lysosomal membrane fuse and form autophagolysosome (sometimes called autolysosome). In mammalian cells, this process is more complicated than in *S. cerevisiae.* Autophagosome fuses first with early and late endosomes which provide not only compounds to be degraded, but also factors required for the fusion between autophagosome and lysosome. It appears that endosomes lower the pH inside autophagosomes, creating favorable conditions for actions of lysosomal hydrolases (Glick et al. [@CR26]). There are several proteins regulating the fusion, including LAMP-2 (Tanaka et al. [@CR145]), monomeric GTP-ases (Rab7, Rab22, Rab24), Rubicon and proteins from the SNARE family (SNAP (Soluble NSF Attachment Protein) REceptor) (Yang et al. [@CR167]). Mutations in the gene coding for the Rab7 protein impair the fusion of autophagosomes with late endosomes and lysosomes (Gutierrez et al. [@CR31]; Yang et al. [@CR166]). Proteins from UVRAG family enhance the Rab7 activity, which promotes such fusions, however, the same family negatively regulates autophagosome maturation when interacting with the Rubicon protein (Wong et al. [@CR163]).

The fusion of autophagosome with lysosome requires also cytoskeleton elements. It was demonstrated that compounds which destabilize microtubules also inhibit autophagosome maturation. In cells treated with cytochalazine D, which blocks actin polymerization, a decrease in number of autophagosomes and autophagolysosmes was observed. Moreover, after treatment with nocodazole, which interferes with microtubule dynamics, the fusion of autophagosome with lysosome was blocked (Köchl et al. [@CR57]). On the other hand, taxol, which stabilizes microtubules, caused an increase in efficiency of autophagolysosome formation (Mariňo and López-Otín [@CR77]; Yang et al. [@CR166]).

Lysosomal degradation {#Sec7}
---------------------

Inside the autophagolysosme, there is an acid environment, which assures optimal pH for action of acid hydrolases which digest compounds enclosed inside this structure, together with its internal membrane. Thus, autophagolysosomes become single-membrane structures containing degraded compounds of the cytoplasm (Roy and Debnath [@CR116]).

Autophagy activation pathways {#Sec8}
=============================

In the regulation of the autophagy process, there are several signaling pathways. They can be generally divided into mTOR-dependent and mTOR-independent ones. The mTOR protein is an evolutionarily conserved 289 kDa serine-threonine kinase. It plays roles not only in autophagy regulation but also controls transcription of genes and translation of proteins involved in microtubule dynamics. Moreover, it influences growth and proliferation of cells, as well as glucose metabolism (Pattingre et al. [@CR98]). Through integration of intracellular signaling and growth factors, this kinase maintains the balance between protein biosynthesis and cell growth. It is also a sensor for energetic molecules in the cell, the ATP level, and the redox state (Roy and Debnath [@CR116]).

Among the autophagy stimulation pathways, the mTOR-dependent ones include: PI3K/Akt/TSC/mTOR, AMPK/TSC/mTOR, and Rag/mTOR pathways. Although the mTOR kinase is considered the main regulator of autophagy, there are also mTOR-independent pathways of autophagy activation. They include: Ca2+/calpain, inositol-dependent, cAMP/EPAC/PLC, and JNK1/Beclin-1/PI3K pathways. Both mTOR-dependent and mTOR-independent pathways are described below and summarized schematically in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Pathways of autophagy stimulation. Detailed description is provided in the text

The PI3K/Akt/TSC/mTOR pathway {#Sec9}
-----------------------------

The PI3K/Akt/TSC/mTOR pathway is initiated under conditions of a lack or low level of insulin or growth factors, which makes the insulin receptor inactive (Sarbassov et al. [@CR119]; Massacesi et al. [@CR78]). This results in a lack of phosphorylation of its substrate, the IRS1 protein, which in turn, cannot interact with the PI3K complex and activate it. Inactive PI3K complex is not able to promote the conversion of phosphatidilinositol-4,5-biphosphate (PtdIns(4,5)P2) to phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3). The role of PtdIns(3,4,5)P3 is recruitment of the PDK1 kinase to the cellular membrane, however, deficiency of PtdIns(3,4,5)P3 results in a lack of activity of PDK1 that is not able to phosphorylate the Akt kinase (Sarkar [@CR120]; Ravikumar et al. [@CR108]). Therefore, Akt remains inactive, and no phosphorylation of the TSC complex, composed of the TSC1/2 heterodimer, is possible (Huang and Manning [@CR42]). Dephosphorylated TSC complex has a GAP (GTPase-activating protein) activity which allows it to stimulate Rheb GTPase, and Rheb remains in the GDP-bound form. This Rheb form is not able to interact with the Raptor protein which is a component of the complex 1 of mTOR kinase (mTORC1). Thus, mTOR remains inactive and cannot interact with the ULK1-Atg13-FIP200 complex (Sarkar [@CR120]), which results in a lack of phosphorylation of ULK1 and Atg13 proteins. This leads to the feedback regulation, as dephosphorylated ULK1 is activated which leads to phosphorylation of Atg13, FIP200 and ULK1 itself. In fact, this triggers formation of the autophagosome (Yang et al. [@CR166]).

In addition to the above mechanism, due to inactivation of the Akt kinase, the FoxO3 transcription factor is not phosphorylated. As such, it migrates to the nucleus and stimulates expression of genes coding for proteins involved in the autophagy process, i.e. LC3 (autophagosome formation), Vsp34 (activation of the JNK1/Beclin-1/PI3K pathway), and ULK1 (induction of the PI3K/Akt/TSC/mTOR pathway) (Stitt et al. [@CR142]). Moreover, inhibition of the mTOR kinase leads to dephosphorylation of TFEB (transcription factor EB). This transcription factor is also translocated to the nucleus and stimulates expression of genes involved in the formation of autophagosomes and lysosomal biogenesis (Vodicka et al. [@CR156]; Roczniak-Ferguson et al. [@CR113]).

The AMPK/TSC/mTOR pathway {#Sec10}
-------------------------

This pathway influences the autophagy activation by a sudden change in the energetic state of the cell, a lack of growth factors or metabolic stress (Meijer and Codogno [@CR81]). AMPK is a cellular energy sensor, thus providing information to the cell about changes in the ATP/ADP ratio (Hardie [@CR33]). Changes in this ratio lead to activation of the LKB1 kinase, resulting in phosphorylation, and thus activation of the AMPK kinase (Shaw et al. [@CR135]). This allows phosphorylation of the TSC2 protein in the TSC complex. Interestingly, this AMPK-mediated phosphorylation unmasks another phosphorylation side in the target protein, which is then used to introduce another phosphate group by the GSK-3β kinase. One should note that under starvation conditions, the AMPK kinase phosphorylates TSC2 directly, without LKB1 involvement. Irrespective of the mechanism leading to TSC2 phosphorylation, this causes appearance of the GDP-bound Rheb form and inhibition of its interaction with mTOR, leading to autophagy induction (Inoki et al. [@CR43], [@CR44]).

The Rag/mTOR pathway {#Sec11}
--------------------

Activation of autophagy by the Rag/mTOR pathway depends on the availability of amino acids (Sarkar [@CR120]). There are two receptors in the cell membrane responsible for detection of these compounds. The first one is the SLC1A5 (solute carrier 1A5) receptor, able to bind and transport L-glutamine from environment to the cell. Increased concentration of L-glutamine stimulates the heterodimeric bidirectional carrier, SLC7A5-SLC3A2, which removes it from the cell, but at the same time transports other amino acids into the cell (Nicklin et al. [@CR93]). Under conditions of amino acid deficiency, or in the case of the dysfunction of the above mentioned receptors, these compounds cannot be caught by the complex of GTPases: Rag (Ras-related GTP-binding protein), regulator and v-ATPase, localized in the lysosomal membrane. Rag GTPases occur as heterodimers, composed of subunit A or B, connected to subunit C or D (Zoncu et al. [@CR180]). In the presence of amino acids, the heterodimer is activated to form a conformation in which Rag A/B is bound to GTP, and Rag C/D is bound to GDP. In contrast, in the lack of amino acids, Rag A/B is bound to GDP and Rag C/D is bound to GTP (Kim and Kim [@CR51]), and this conformation is inactive, thus, unable to interact with the Raptor protein that is a part of the mTORC1 complex. Therefore, the complex cannot bind to the lysosomal surface, and it is not activated by GDP-Rheb (Sancak et al. [@CR118]). The inactive mTOR kinase cannot interact with the ULK1-Atg13-FIP200 complex, enabling initiation of the autophagosome formation (Hosokawa et al. [@CR40]).

The Ca^2+^/calpain pathway {#Sec12}
--------------------------

The Ca2^+^/calpain pathway is activated under conditions of any severe changes of physiological conditions. Another factor influencing this pathway is concentration of Ca^2+^ ions inside the cell, which activate calpains, proteins belonging to the family of cysteine proteinases (Goll et al. [@CR28]). They can be activated not only by Ca^2+^ ions transported into the cell through the calcium channel, but also by the ions liberated from endoplasmic reticulum (Gordon et al. [@CR29]; Williams et al. [@CR162]; Ganley et al. [@CR23]).

Autophagy induction by the Ca2^+^/calpain pathway can be stimulated by antagonists of Ca2^+^ canals type L (Williams et al. [@CR162]; Zhang et al. [@CR170]). They inhibit the inflow of the ions to the cell, thus, calpains are not activated. Generally, high Ca2^+^ levels and calpain activation negatively regulate the autophagosome formation and its fusion with lysosome (Sato-Kusubata et al. [@CR125]). However, when the Ca2^+^ canals are closed, the level of Ca2^+^ ions is low, calpains are not activated, and the autophagy process can be initiated (Williams et al. [@CR162]).

It is worth mentioning that the Ca2^+^/calpain pathway is connected to the pathway dependent on cAMP (described below). When nutrients are available and Ca2^+^ canals are open, active calpains stimulate dissociation of the α subunit of the G protein and its activation which, in turn, activates the AC (adenylate cyclase) protein to produce cAMP from ATP. In the deficiency of Ca2^+^ ions, this pathway is not activated, cAMP is not synthesized, which stimulates autophagy through the cAMP/EPAC/PLC pathway (Sato-Kusubata et al. [@CR125]; Williams et al. [@CR162]).

The inositol-dependent pathway {#Sec13}
------------------------------

One of autophagy activation pathways is a cascade of reactions dependent on the intracellular levels of inositol. This cascade is stimulated by blocking of the G protein-coupled receptor, which mediates activation of the phospholipase C (PLC). Under such conditions, inositol triphosphate (IP3) and diacylglycerol (DGA) are not formed from 4,5-phosphatidilinositol-bis-phosphate (PIP2) (Berridge [@CR5]). Free inositol arises as a result of hydrolysis of two phosphate moieties from IP3 by inositol polyphosphatase (IPPase) and inositol-5'-phosphatase, and subsequent hydrolysis of inositol phosphate by inositol monophosphatase (IMPase) (Majerus [@CR73]). When PIP2 cannot be converted to IP3, no free inositol is present which causes a lack of inhibition of autophagosomal membrane formation; this triggers the autophagy process.

There is a link between the inositol-dependent pathway and the Ca^2+^/calpaine pathway. Under normal physiological conditions, IP3 interacts with its receptor (IP3R) located in the endoplasmic reticulum which stimulates an increase in the level of Ca^2+^ ions in the cell and activation of calpains. In the absence of IP3, due to inhibition of the inositol-dependent pathway, the Ca^2+^/calpaine pathway is also impaired due to a lack of interaction with IP3R and low level of Ca^2+^ ions (Berridge [@CR5]; Berridge et al. [@CR6]).

The cAMP/EPAC/PLC pathway {#Sec14}
-------------------------

The autophagy is regulated by 3'5'adenosinemonophosphate (cAMP), independently from the mTORC1 kinase. cAMP is synthesized by adenylate cyclase from adenosine-5'-triphosphate (ATP) (Williams et al. [@CR162]). Major activators of this pathways belong to agonists of imidazoline receptor (which acts to decrease the cAMP level). By activation of this receptor, these compounds cause a decrease in cAMP concentration in the cell (Williams et al. [@CR162]). This results in a lack of EPAC (exchange protein directly activated by cAMP) activation, and resultant maintenance of the Rap2B protein in its inactive state (Gloerich and Bos [@CR27]; Breckler et al. [@CR8]). Under such conditions, phospholipase C (PLC) is not activated, and PIP2 cannot be converted to IP3 (see the inositol-dependent pathway, described above) (Sarkar et al. [@CR122]). Both cAMP and IP3 are inhibitors of the phagophore formation, thus, impairment of the above described cascade results in autophagy activation.

The JNK1/Beclin-1/PI3K pathway {#Sec15}
------------------------------

The phosphoinositol kinase 3 (PI3K) complex consists of several class of enzymes. In the JNK1/Beclin-1/PI3K pathway, the crucial role is played by class III (PI3KC3) which include Beclin-1, pVps34, and pVps15 (Pattingre et al. [@CR98]). Starvation conditions result in phosphorylation of the Bcl-2 protein by the stress-activated c-Jun-N-terminal protein kinase 1 (JNK1). This leads to inhibition of interaction between Bcl-2 and Beclin-1, and dissociation of the phosphorylated Bcl-2 form from the Bcl-2-Beclin-1 complex. Liberated Beclin-1 can interact with hVps34, which is a prerequisite to form the Beclin-1-hVps34-hVps15 complex. The latter complex directly stimulates formation of the autophagosome (Pattingre et al. [@CR97]; Wei et al. [@CR158]).

Stimulation of autophagy as a therapeutic approach for treatment of metabolic neurodegenerative diseases {#Sec16}
========================================================================================================

A large group of disorders in which autophagy induction might be profitable for treatment are metabolic brain diseases. Most of them is caused by the aggregation of improperly folded proteins which accumulate in neurons and cause their damage, leading to various severe psycho-motoric disorders. Pharmacologic induction of autophagy is one of the most promising approaches. An alternative pathway, the proteasomal degradation, is significantly less efficient in cells of patients due to ongoing proteasome damage by newly formatting protein aggregates (Zheng et al. [@CR177]).

Studies on the therapeutic use of autophagy activators in neurodegenerative diseases are carried out in many laboratories around the world. However, researchers are still looking for compounds which not only stimulate degradation of accumulated, toxic macromolecules, but also are safe and suitable for the use in long-term use without severe adverse effects. The strategy of pharmacological stimulation of toxic macromolecules' degradation is being tested using both cellular and animal models of neurodegenerative diseases, while due to relatively recent onset of such studies, there are only a few completed clinical trials, and most of them are either ongoing or at the stage of patients' recruitment. In addition, new autophagy stimulators are being discovered which give promising results in experiments performed *in vitro* or with the use of animal models.

The most frequently used models of neurodegenerative disorders in studies on efficacy of autophagy stimulation are Huntington disease (a monogenic disorder whose etiology is well established), amyotrophic lateral sclerosis or ALS (a disease with predominance of one gene dysfunction, but with contribution of other factors), Alzheimer disease and Parkinson disease (disorders caused by multiple factors, but including inherited forms in which mutations in particular genes occur), and prion diseases (disorders which can be caused by a mutation, but prone to develop due to protein-protein interactions). The common feature of all these diseases is accumulation of misfolded proteins in neurons and a lack of effective treatment. Therefore, autophagy induction appears to be a promising potential therapeutic strategy. The above mentioned diseases are summarized briefly in Table [1](#Tab1){ref-type="table"}.Table 1Neurodegenerative diseases which are model disorders in studies on autophagy inductors as potential therapeuticsDiseaseClassificationStored materialCause of diseaseInheritanceAlzheimer disease (AD)Proteinopathy (amyloidose, tauopathy)β-amyloid; hyperphosphorylated tau proteinMutation (familial form); unknown -- perhaps multifactorial (sporadic form)Autosomal dominant (familial form); multifactorial (sporadic form)Parkinson disease (PD)Proteinopathy (Syncleinopathies)α-synuclein; parkinMutation (familial form); unknown -- perhaps multifactorial (sporadic form)Unclear; multifactorial (sporadic form)Huntington disease (HD)ProteinopathyHuntingtinMutationAutosomal dominantAmyotrophic lateral sclerosis (ALS)ProteinopathySuperoxide dysmutase (SOD)Mutation (familial form); unknown -- perhaps multifactorial (sporadic form)Unclear; multifactorial (sporadic form)Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker diseasePrion diseasePrP (prion protein)Mutation (familial form); interactions between wild-type and misfolded proteinsAutosomal dominant (familial form); presence of the misfolded protein form

Compounds activating autophagy and their therapeutic potential in treatment of metabolic brain diseases {#Sec17}
=======================================================================================================

Rapamycin {#Sec18}
---------

One of the best known autophagy activators is rapamycin which inhibits the mTOR kinase activity. This compound is widely used as a drug inhibiting lymphocyte activation, thus, as an immunosuppressant it is employed in treatment of patients subjected to transplantations. Rapamycin binds to the cytosolic protein FKBP-12, and following formation of the tertiary complex with mTOR, the kinase activity of this protein is inhibited. As a result, the mTOR kinase substrate, 4EBP1, is not phosphorylated (Jacinto et al. [@CR45]) which leads to destabilization of the mTOR-Raptor complex (Kim et al. [@CR52]).

Rapamycin is used in studies on neurodegenerative diseases in both *in vitro* and *in vivo* models. Studies on cellular models gave promising results, indicating a possibility to enhance degradation of proteins which cause different disorders, including mutant huntingtin (mHTT) (Ravikumar et al. [@CR106]; Sarkar et al. [@CR123]) and alpha-synuclein (Webb et al. [@CR157]). Nevertheless, more studies are being conducted with animal models. Effects of rapamycin on Huntington's disease were tested in studies employing models of *Drosophila melanogaster* (Ravikumar et al. [@CR107]; Sarkar and Rubinsztein [@CR121]; Berger et al. [@CR4]), zebrafish (Williams et al. [@CR162]; Sarkar et al. [@CR124]), and mice (Ravikumar et al. [@CR107]). Animal experiments indicated a decrease in levels of mHTT aggregates, amelioration of neurodegeneration and improved animal behavior. Despite encouraging results of these studies, clinical trials with the use of rapamycin for treatment of HD have not been started yet.

Another disease in which rapamycin was tested using animal models is AD. Levels of beta-amyloid and hyperphosphorylated tau protein were determined as basic parameters considered in AD pathology. Experiments with AD mice overproducing the mutated gene coding for the tau protein indicated a highly elevated level of hyperphosphorylated form of this protein, while treatment with rapamycin caused its significant reduction and a decrease in number of neurofibrylar tangles (Ozcelik et al. [@CR95]). Similar tendency was observed in mice producing toxic beta-amyloid, where rapamycin decreased the amount of this compound in the brain and improved the cognitive deficits (Spilman et al. [@CR141]; Majumder et al. [@CR74]; Zhang et al. [@CR173]; Caccamo et al. [@CR10]).

In rapamycin-treated cellular models of PD, levels of alfa-synuclein aggregates were decreased due to stimulation of both lysosomal (autophagy) and proteasomal degradation (Webb et al. [@CR157]).

Another example of the disease in which rapamycin was tested as a potential drug is Gerstmann-Sträussler-Scheinker syndrome, belonging to the group of prion diseases. Studies on the mouse model of this disease revealed prolonged life span, delayed symptoms and milder phenotype in animals treated with rapamycin (Cortes et al. [@CR14]). On the other hand, different results were observed in the mouse model of ALS. Despite induction of autophagy, in rapamycin-treated mice, degeneration of motor neurons was enhanced relative to untreated controls and the life span was shorter (Zhang et al. [@CR172]). No significant differences were observed in the levels of aggregated superoxide dysmutase (SOD) between both groups of animals. The cause of enhanced neurodegeneration in mice treated with rapamycin remains unknown, but it seems unlikely to be due to toxicity of mutated SOD.

Despite many encouraging results of studies on rapamycin in cellular and animal models of neurodegenerative diseases, clinical trials have not been performed yet. Some doubts appeared due to the presence of adverse effects occurring in patients treated with this compound as an immunosuppressant. They include severe infections, hemolytic-uremic syndrome, cancer, leukopenia, and bone atrophy. Such adverse effects might be perhaps acceptable in a short-term treatment, for example in the transplantation procedures, however, in a long-term use, which is necessary in neurodegenerative diseases, they would be dangerous for patients.

L-NG-Nitroarginine methyl ester {#Sec19}
-------------------------------

L-NAME (L-NG-Nitroarginine methyl ester) is an activator of the PI3K/Akt/TSC/mTOR pathway and mTOR-independent JNK1/Beclin-1/PI3K pathway. This compound inhibits formation of nitric oxide, which negatively regulates activity of the JNK1 kinase, leading to impairment of formation of the hVps34/Beclin 1 complex that is required for autophagosome formation. Thus, L-NAME-mediated deprivation of the NO level promotes creation of autophagosomes and enhances efficiency of autophagy. This mechanism has been employed in studies on cellular and animal models of HD (Sarkar et al. [@CR124]). Recent studies on cancer cells indicated that L-NAME induces also another pathway of autophagy stimulation, namely the PI3K/Akt/TSC/mTOR pathway (Zhu et al. [@CR179]). However, determination of relevance of this mechanism in neurodegenerative diseases requires further studies. L-NAME has been tested in studies on AD. Intracranial injection of this compound resulted in improvement of memory and learning of AD mice (in the Morris water maze test) and an increase of the level of autophagy markers, relative to untreated animals (Shariatpanahi et al. [@CR134]).

Trehalose {#Sec20}
---------

Trehalose activates both mTOR-dependent and mTOR-independent pathways of autophagy stimulation. It activates the AMPK/TSC/mTOR pathway, however, it also enhances expression of the gene coding for beclin, thus, it acts by stimulation of the JNK1/Beclin-1/PI3K pathway, which is an mTOR-independent mechanism of autophagy activation (Vidal et al. [@CR154]). Translocation of the FoxO transcription factor, a substrate for the Akt kinase (in the mTOR-dependent pathway) has been demonstrated (DeBosch et al. [@CR17]). This indicates that trehalose, similarly to L-NAME, is an inductor of at least two pathways leading to autophagy stimulation. This is supported by results indicating involvement of trehalose in the regulation of the AMPK-dependent pathway (DeBosch et al. [@CR17]).

Promising results were obtained in studies on cellular models of PD in which induction of autophagy (Zhao et al. [@CR176]) or proteasomal pathway of protein degradation (Lan et al. [@CR63]) is accompanied with a decrease in the level of quickly aggregating form of A53T-mutated alpha-synuclein. In addition, the cells producing this toxic protein were protected against apoptosis.

In studies on the cellular AD model, it was found that the level of endogenous tau protein was reduced and the toxicity caused by formation of aggregates was alleviated after treatment with trehalose (Krüger et al. [@CR60]). It was, therefore, suggested, that this compound might be effective not only in treatment of AD but also other tauopathies. Studies on animal models demonstrated a decreased number of neurons with tau protein aggregates and lower numbers of these aggregates in cells, as well as improved viability of neurons (Schaeffer et al. [@CR126]) as a results of treatment with trehalose. Another study with similar approach indicated improvement of motor functions of animals and alleviation of fear (Rodríguez-Navarro et al. [@CR114]).

Decreased quantity of mHTT aggregates and significant improvement of behavior were observed in analogous studies with HD mouse model (Perucho et al. [@CR100]). When trehalose was tested in cellular models of ALS, autophagy-dependent degradation of SOD1 aggregates led to increased viability of neurons. These results were corroborated by studies on the animal model of ALS, in which prolongation of the life span was observed (Castillo et al. [@CR12]).

Resveratrol {#Sec21}
-----------

Resveratrol is another stimulator of the AMPK/TSC/mTOR pathway. It activates the AMPK kinase which leads to stimulation of the autophagy process (Burkewitz et al. [@CR9]). Efficiency of this compound in removal of toxic protein has been tested in various diseases. Resveratrol has induced autophagy and enhanced degradation of mHTT in the cellular model of HD, in which neuroblastoma SH-SY5Y line was used. Moreover, level of the Atg4 (which is decreased in mHTT-accumulating cells) normalized (Vidoni et al. [@CR155]). This compound has also been used in the 3-nitropropionic acid (3-NPA)-induced rat model of HD. However, it is worth to note that in such animals, neurodegeneration occurs due to changes in mitochondrial metabolism which leads to (i) production of reactive oxygen species, (ii) changes in cellular energetics, and (iii) induction of apoptosis. As a consequence, hypo- and hyper-motoric changes appear which resemble symptoms of HD. Nevertheless, chorea, dyskinesis and dystony never occur in 3-NPA-treated murine models, while they are the most characteristic symptoms in humans. Moreover, this compound does not cause appearance of mHTT, the primary cause of the disease, thus, only secondary effects can be tested (Túnez et al. [@CR151]). Hence, mechanisms of autophagy-mediated degradation of mHTT could not be studied in this model, and the tests included only anti-oxidant properties of resveratrol, which caused an increase in the level of glutathione and a decrease in levels of nitrites, as well as less efficient peroxidation of lipids. Thus, results of memory and motoric tests were better in treated animals than in controls (Kumar et al. [@CR62]). On the other hand, experiments with transgenic HD mice have also been performed. It was suggested that activation of SIRT1 (mammalian sirtuin) by resveratrol increases viability of neurons (Ho et al. [@CR36]). However, this compound did not affect changes in the striatum, motor functions and life span of mice.

To test effects of resveratrol on PD, mouse neuroblastoma cell lines (N2a cells) were treated with this compound in combination with β-cyclodextrin. Number of alpha-synuclein aggregates decreased and viability of the cells increased (Gautam et al. [@CR24]). In animals, PD can be induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine), which is converted to MPDP^+^ (1-methyl-4-phenyl-2,3-dihydropyridinium), and then to the active metabolite MPP^+^ (1-methyl-4-phenyl-pyridinium) by astrocytes and acts as an inhibitor of complex I of the mitochondrial electron transport system. This active toxin is catched by dopaminergic neurons in striatum and leads to their degeneration (Porras et al. [@CR103]). When resveratrol was administered to mice before MPTP, a protection against neurodegeneration was observed, dopamine was kept at normal levels, and animal behavior was significantly less changed relative to animals treated solely with the toxin. Molecular studies indicated that SIRT1 is activated by resveratrol which leads to LC3 deacetylation and induction of autophagy. As a result, number of alfa-synuclein decreased in dopaminergic cells (Guo et al. [@CR30]). Other tests, performed with the use of the rat model, suggested an anti-oxidative mechanism of resveratrol action, since the red-ox balance has been re-established, endoplasmic reticulum stress was alleviated, and expression of genes coding for caspases was impaired, which might protected cells against apoptosis (Gaballah et al. [@CR22]).

Calcium canal antagonists {#Sec22}
-------------------------

Antagonists of calcium canals, which also activate the Ca^2+^/calpain pathway, are relatively often tested in metabolic brain diseases. The list of such compounds include: latrepirdine, verapamil, loperamide, nitrendipine, nilvadipine, nimodipine, amiodarone, niguldipine, nicardipine, pimozide, penitrem A, fluspirilene, and trifluoperazine. When the calcium channel is blocked, the intracellular calcium level drops rapidly, thus, calpains are inactivated which stimulates autophagosome formation. Such compounds were tested in cellular models of HD, and it was found that they caused reduction of the mHTT level (Zhang et al. [@CR170]; Williams et al. [@CR162]).

Latrepiridine was tested in the cellular model of AD, and decreased levels of calcium ions were correlated with increased viability of cells (Lermontova et al. [@CR67]). However, in that work, autophagy was not suggested as a mechanism leading to such improvement. Experiments with animal models of AD indicated decreased levels of beta-amyloid deposits in the brain and increased levels of autophagy markers in latrepiridine-treated mice (Bharadwaj et al. [@CR7]). In similar experiments, improvement in cognitive tests was reported (Lermontova et al. [@CR66]). However, a clinical trial phase III with this compound as a potential anti-AD drug, gave negative results (Chau et al. [@CR13]; Sweetlove [@CR144]; <http://www.alzforum.org/news/research-news/dimebon-disappoints-phase-3-trial?id=2387>). Similarly, phase III clinical trial with HD patients failed to demonstrate improvement after treatment with latrepiridine ([https://www.genengnews.com/gen-news-highlights/phase-iii-failure-leads-medivation-and-pfizer-to-ditch-dimebon-for-huntington-disease/81244981/](https://www.genengnews.com/gen-news-highlights/phase-iii-failure-leads-medivation-and-pfizer-to-ditch-dimebon-for-huntington-disease/81244981)).

Verapamil has been tested in experiments with a HD mouse model. This drug caused improvement in motoric activity and keeping balance by animals (Kalonia et al. [@CR47]). Although verapamil has not been tested in clinical trials for HD, its efficacy was assessed in treatment of ALS patients. However, 5-month treatment did not result in improvement of the disease parameters (Miller et al. [@CR87]).

When nitrendipine and nilvadipine were studied using AD models, inhibition of beta-amyloid accumulation *in vitro* and its enhanced degradation *in vivo*, accompanied with memory improvement in mice, were observed (Paris et al. [@CR96]). Interestingly, quite similar results were obtained during experimental therapy of AD patients when nilvadipine and nimodipine prevented the progression of congnitive problems (Nimmrich and Eckert [@CR94]). On the other hand, in the clinical trial phase III with ALS patients, nimodipine appeared ineffective and many adverse effects were reported, including diarrhea, nausea, and lightheadedness (Miller et al. [@CR86]).

Amiodarone has been tested mainly as a potential anti-AD drug. Experiments were conducted *in vitro* and *in vivo* (with the Guinea pig model). Amiodarone was used as a compound which elevates pH, thus, secretases that cut the APP protein (the amyloid precursor) and require acidic environment, were inactivated. Thus, the level of amyloid decreased, however, a mechanism involving stimulation of autophagy was not considered, though the authors suggest that elevation of pH is perhaps not the only way of action of the tested compound (Mitterreiter et al. [@CR89]).

Pimozide, is already used in medicine for treatment of schizophrenia and psychotic disorders (Mothi and Sampson [@CR90]). However, its positive effects were observed also in HD. Experimental therapy with a low number of patients indicated an improvement in hyperkinesia (Girotti et al. [@CR25]). Studies with the mouse model of AD which overproduces hyperphosphorylated tau protein, indicated that intraperitoneal administration of pimozide resulted in reduction of aggregates of this protein and to memory improvement in animals (Kim et al. [@CR54]). Interestingly, when considering a possible molecular mechanism of pimozide action, the authors did not consider the calcium channel-dependent pathway. On the contrary, they have detected an increased level of phosphorylation of AMPK and ULK1 kinases, and inhibition of the mTOR kinase activation. They have suggested that pimozide may stimulate as yet unknown pathway of autophagy induction which is dependent on AMPK-ULK interactions, with no involvement of mTOR (Kim et al. [@CR54]). One case of an AD patient treated with pimozide for 5 weeks has been described, and alleviation of dementia was noted; the effects remained unchanged for next 9 months (Renvoize et al. [@CR111]). Despite these results, no clinical trial with this compound was reported to date.

Trifluoperazine has been tested as a potential anti-HD and anti-AD drug. However, it was suggested that this compound may inhibit apoptosis, and stimulation of autophagy has not been considered (Lauterbach [@CR64]). Studies with patients included only a very limited number of individuals, though the results were quite encouraging (Stokes [@CR143]). On the other hand, trifluoperazine was widely tested for treatment of AD. However, a clinical trial with this compound indicated that life span of treated patients was shortened by 12 months relative to untreated controls (Ballard et al. [@CR2]). In another clinical trial, no improvement of the disease symptoms could be find (Ballard et al. [@CR1]). Interesting studies were conducted on a PD mouse model, characterized by moderate expression of the gene coding for synucleine, thus the time of death of neurons could be determined precisely. It was found that non-induced autophagy is impaired by accumulated synuclein, while trifluoroperazine-induced autophagy causes a delay in neurons' death (Höllerhage et al. [@CR37]). When screening for anti-PD compounds was conducted using a zebrafish model, trifluoperazine was identified as a molecule preventing the loss of neurons. It was demonstrated that apart from blocking calcium channels, trifluoperazine stimulated translocation of the transcription factor EB (TFEB; a master regulator for lysosomal biogenesis that also activates autophagy, when present in the nucleus in a non-phosphorylated form, by enhancing transcription of relevant genes) which is a substrate for the mTOR kinase. Therefore, this compound is another factor which can stimulate autophagy through more than one pathway (Zhang et al. [@CR174]).

Studies on other blockers of calcium channels (loperamide, niguldipine, nicardipine, panitrem A, and fluspirilene) as anti-neurodegenerative agents were terminated after *in vitro* studies (Zhang et al. [@CR170]; Williams et al. [@CR162]) due to adverse effects reported in the meantime by researchers using them for treatment of other diseases. These adverse effects included: constipation, dizziness, nausea, paralytic ileus, angioedema, anaphylaxis reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiform, urinary retention, and heat stroke.

Calpastatin {#Sec23}
-----------

Calpastatin inhibits activities of calpains, thus, inhibition of autophagosome formation is abolished. Overproduction of calpastatin induced autophagy decreased levels of mHTT, improved motor functions, and delayed appearance of other symptoms in the mouse model of HD (Menzies et al. [@CR83]). Importantly, prolonged administration of calpastatin did not cause any severe adverse effects in animals. In studies on the cellular AD model, an inhibitor of histone deacetylase, trichostatin A, which also increases production of calpastatin, caused an increase in viability of cells (Seo et al. [@CR131]). These results are in agreement with observations that silencing of expression of calpastatin-encoding gene causes changes in cytoskeleton and lowers cell viability (Rao et al. [@CR105]). Moreover, long-term activation of calpains causes overstimulation of many proteases, which leads to degradation of a number of cellular substrates, including cytoskeleton elements and membrane receptors involved in homeostasis maintenance. When calpastatin is overproduced, such effects can be diminished (Schoch et al. [@CR130]). Overexpression of the calpastatin gene in the mouse model of PD resulted in reduction of the number of alpha-synuclein aggregates and improved signal transduction through synapses (Diepenbroek et al. [@CR18]).

Minoxidil {#Sec24}
---------

Minoxidil activates potassium channels which prevents the transport of calcium ions into the cell, leading to calpains inactivation and enhanced autophagy (Renna et al. [@CR110]). When cellular models of PD and HD were investigated, minoxidil induced the autophagy process and a decrease in levels of alpha-synuclein and mHTT was observed which was accompanied with increased cell viability (Williams et al. [@CR162]). However, this compound has not been tested yet in animal models.

Lithium {#Sec25}
-------

Lithium is tested as a potential drug for many diseases affecting central nervous system (CNS). This agent inhibits activity of inositol monophosphatase, decreasing the level of inositol and IP3 which allows formation of the autophagosome membrane (Sarkar et al. [@CR122]). However, lithium negatively regulates also activity of another enzyme, GSK-3β, causing stimulation of the mTOR kinase and autophagy inhibition. Therefore, it was proposed to combine the use of lithium and rapamycin (an inhibitor of mTOR). This approach appeared significantly more effective than the use of each component separately (Sarkar et al. [@CR123]). However, in studies with the 3-NPA-induced HD rat model, treatment with LiCl for 8 days caused an increase in pathological changes in the brain (Milutinović [@CR88]). On the other hand, it is worth remaining that 3-NPA does not cause the appearance of mHTT aggregates, thus, this is not an adequate model for testing potential drugs which might activate autophagy. In such studies, genetic models of mHTT would be much more relevant. It was also reported that lithium causes a decrease in the level of histone deacetylase (HDAC1) which is correlated with effective degradation of mHTT (Wu et al. [@CR164]). Lithium has also been used in experimental therapy in which 3 patients suffering from HD were involved. In one patient, some neurological parameters were improved, but no changes in chorea could be observed. The second patient responded with improvement in chorea with no neurological changes. In the third patient, stabilization of all symptoms, but no improvement, was noted. Nevertheless, all these patients received also other drugs, including carbamazepine, which makes interpretation of the results very difficult (Danivas et al. [@CR16]). Other clinical trials with HD patients also did not give conclusive results regarding efficacy of lithium due to extremely different responses of various persons (Scheuing et al. [@CR127]).

When mice overproducing hyperphosphorylated tau protein were treated with lithium, a significant improvement in behavior and cognitive functions was observed, levels and phosphorylation of tau decreased, as did efficiency of beta-amyloid formation, and levels of autophagy markers increased (Shimada et al. [@CR137]; Zhang et al. [@CR171]). Efficacy of lithium in the mouse model of PD was tested in a combined therapy with valproic acid. Improvement in behavior and an increase in the number of dopaminergic neurons were evident. Deprivation of dopamine and its metabolite, dihydroxyphenyloacetic acid, was less pronounced than in untreated animals (Li et al. [@CR68]). Analogous combination of drugs was tested in the mouse model of HD. Treated animals expressed improvement in motoric functions and memory (as tested in the Morris water maze). Reduction of the level of mHTT aggregates and less pronounced loss of neurons in striatum were observed. Interestingly, expression of genes coding for proteins involved in mitochondrial metabolism, antioxidative response, apoptosis and anti-inflammatory reactions were significantly modulated (Linares et al. [@CR70]). These results indicate the broad spectrum of biological activities of lithium and valproic acid, as suggest that a complex network of processes is involved in the pathogenesis of HD.

Valproic acid {#Sec26}
-------------

Valproic acid inhibits activity of myo-inositol-1-phosphate synthase, one of enzymes involved in the metabolism of inositol (Shaltiel et al. [@CR133]), thus, causing a decrease of the level of the latter compound and activation of autophagy. Combination of valproic acid and lithium was tested in clinical trials with HD patients. However, in most cases either a lack of effects or only stabilization of symptoms (with no improvement) were observed (Scheuing et al. [@CR127]).

AD model cells were treated with valproic acid, and no changes with the total amount of beta-amyloid were demonstrated while level of beta-amyloid oligomers (which are suggested to be more toxic) decreased and level of monomers increased, relative to untreated control cells (Williams and Bate [@CR160]). This may suggest that beta-amyloid oligomers are converted to monomers in valproic acid-treated cells. Streptozotocin (STZ)-induced rat model of AD has been used in *in vivo* studies. Intraventricular injection of STZ provokes neurodegeneration and accumulation of beta-amyloid and hyperphosphorylated tau protein, thus, mimicking the sporadic form of AD. Decreased levels of acetylcholine and neprylysine, and increased activity of acetylcholinesterase cause additionally enhanced neurodegeneration and cognitive defects. Treatment with valproic acid resulted in prevention of cognitive deficits and normalization of levels and activities of neurotransmitters (Sorial and El Sayed [@CR140]). Using another animal model of AD, transgenic mice expressing a mutated *APP* gene, effects of valproic acid in males and females were compared. Decreased levels of amyloid plaques were more pronounced in males than in females, while number of synaptic vesicles were similar in both genders. On the other hand, neurodegeneration was prevented more efficiently in males (Long et al. [@CR72]).

Cellular models of PD were used to investigate the mechanism of action of valproic acid. This compound caused reduction of levels of proapoptotic proteins and ROS, while autophagy inhibitors diminished these effects, indicating a crucial role of this process in valproic acid-mediated improvement in PD cellular phenotypes (Zhang et al. [@CR175]). Other *in vitro* studies were based on the use of murine neurons treated with human beta-amyloid. Defects in synaptic proteins and neurotransmitter transporting vesicles were observed. These effects were alleviated by addition of valproic acid into the cell culture. A mechanism has been proposed in which this compound negatively regulates cytoplasmic phospholipase A2 (cPLAS2), whose overactivity correlates with neurodegeneration. Autophagy has been suggested as an additional mechanism of the observed changes in cells (Williams and Bate [@CR159]).

Controversial results were obtained in studies on prion disease. Early studies suggested that valproic acid causes an increased accumulation of PrP in neuroblastoma cells and model cells for the disease. However, administration of valproic acid to Chinese hamsters infected with prions did not cause any effects on the course of the disease (Shaked et al. [@CR132]). Other studies performed with cellular models did not confirm effects of valproic acid on the levels of PrP (Legendre et al. [@CR65]).

Carbamazepine {#Sec27}
-------------

Mechanism of action of carbamazepine is similar to that by valproic acid and lithium (Williams et al. [@CR161]). A decrease in the inositol level arises from deprivation of PIP2 and IP3 (Schiebler et al. [@CR128]). Studies with the mouse model of AD indicated that carbamazepine improved learning abilities and memory, which was correlated with decreased number of amyloid plaques (Li et al. [@CR68]; Zhang et al. [@CR173]). Apart from stimulation of mTOR-independent pathway of autophagy activation, carbamazepine inhibited the mTOR kinase activity. Therefore, it is another example of autophagy stimulation by more than one molecular mechanism (Li et al. [@CR68]).

Since carbamazepine is known as an analgesic, anticonvulsant and antiepileptic drug, it has been used for treatment of HD patients (Danivas et al. [@CR16]). It was proposed that its mechanisms of action is related to blocking calcium channels which cause inhibition of glutamate liberation (Kawata et al. [@CR49]). Intriguingly, autophagy was not considered as a mechanism by which carbamazepine improves symptoms of HD.

An interesting case report has been published in which carbamazepine was administered to a patient suffering from hypertension, myocardial infraction, and atrial fibrillation. When high doses of the drug were used (as the patient became resistant to lower doses), many adverse effects were noted, including memory deficits, confusion, psychomotor slowness, hypersomnia, dysphasia, and postural instability with falls. The patient's condition was continuously deteriorating. Psychological tests indicated attentional deficits, perseverations, severe non-fluent aphasia with paraphasias, and constructional apraxia. The EEG results were similar to those found in patients suffering from Creutzfeldt--Jakob disease. After cessation of treatment with carbamazepine both EEG results and patient's conditions improved considerably. Cognitive deficit and motor dysfunctions normalized. Thus, it was concluded that carbamazepine caused Creutzfeldt--Jakob disease-like symptoms (Horvath et al. [@CR38]).

Clonidine {#Sec28}
---------

Clonidine binds and activates the imidazoline receptor, which leads to a decrease in the level of cAMP in cells (Williams et al. [@CR162]). However, it appears that there is an additional mechanism of action of this compound, namely activation of potassium channels which causes a decrease in concentration of calcium ions in the cytoplasm (Murphy and Freedman [@CR91]). Clonidine was used as one of compounds activating autophagy in the screening for a potential drug for HD and PD. It was effective in reducing amounts of synuclein and mHTT in cells (Williams et al. [@CR162]). *In vivo* experiments were performed with reserpine-treated rat model of Parkinson\'s disease. Following injection of reserpine, severe akinesis was observed which could be prevented by previous treatment with clonidine (Hill and Brotchie [@CR35]). However, stimulation of autophagy was not considered as a potential mechanism of action of this drug. In PD potential therapies concentrate on inhibition of movements while patients suffer also from cognitive deficits and mood swings. When clonidine, as an agonist of adrenergic receptor alpha-2, was tested as a potential drug at early phase of PD in a monkey model (*Macaca fasicularis*), it was found that the treatment caused improvement in concentration and memory (Schneider et al. [@CR129]).

Models of memory deficits were also used in studies on clonidine. In murine models, the symptoms were induced by administration of NMDA (N-methyl-D-aspartate) antagonist MK-801 or by excitotoxic hippocampal damage. Clonidine ameliorated symptoms caused by MK-801, but did not change behavior of rats in which hippocampus was damaged by excitotoxic agents (Bardgett et al. [@CR3]).

The only studies on the use of clonidine in prion disease were performed with the yeast model. However, no significant effects on the level of PrPSC could be observed (Tribouillard-Tanvier et al. [@CR149]).

Rilmenidine {#Sec29}
-----------

Rilmenidine induces the autophagy proces through the cAMP/EPC/PLC pathway. Similarly to clonidine, it binds and activates the imidazoline receptor. It was tested in experiments with cellular HD and PD models, and caused a decrease in levels of mHTT and alpha-synuclein (Williams et al. [@CR162]). In the mouse model of HD, reduction of mHTT levels was also observed but number of aggregates remained unchanged. Although rilmenidine could not prevent the body weight loss, it corrected the muscle parameters and general condition of the organism (Rose et al. [@CR115]). Although a clinical study with 18 HD patients has been conducted, only 12 patients completed this trial. Some cognitive parameters and motor functions were improved (Underwood et al. [@CR152]); however, a study with significantly higher number of patients is necessary to make solid conclusions.

Cellular and animal models of ALS were used to study effects of rilmenidine in this disease. A decrease in mutant SOD1 level was observed in cells in which macroautophagy and mitophagy were also evident. Similarly, administration of this drug to mice suffering from ALS resulted in autophagy induction in motor neurons. Unexpectedly, enhanced degeneration of these neurons was observed under these conditions. Moreover, accumulation of SOD aggregates and a decrease in number of mitochondria occurred in treated animals, and correlated with more severe symptoms relative to untreated mice. It was suggested that too extensive mitophagy could be responsible for these effects (Perera et al. [@CR99]).

Dideoxyadenosine {#Sec30}
----------------

Dideoxyadenosine (2'5'ddA) inhibits the activity of adenylate cyclase which leads to a rapid decrease in the cAMP level in cells, and subsequent stimulation of autophagy. In studies with a cellular model of HD, treatment with 2'5'ddA resulted in decreased levels of mHTT and its aggregates (Williams et al. [@CR162]). No reports were published on the use of this compound in experiments with animal models.

SMER28 {#Sec31}
------

SMER28 appears to induce autophagy through both PI3K/Akt/TSC/mTOR and JNK1/Beclin-1/PI3K pathways (Sarkar et al. [@CR124]). When cellular model of AD was employed, treatment with SMER28 prevented formation of beta-amyloid aggregates in a dose-response mode (Shen et al. [@CR136]). When production of Beclin-1 was impaired, effects of SMER28 were diminished. Similar effects were observed in experiments with silencing of expression of the gene coding for ULK kinase. Therefore, SMER28 appears to stimulate mTOR-dependent and mTOR-independent mechanisms of autophagy activation pathways (Tian et al. [@CR148]).

Concluding remarks {#Sec32}
==================

There are various possibilities to induce autophagy. In this review, mechanisms of these pathways were discussed to indicate how this process can be stimulated, which is in contrast to most other review article that described mechanisms of negative regulations (in fact autophagy is regulated by various inhibitors). Stimulation of autophagy has been considered as a strategy for treatment of various neurodegenerative diseases. Although there are many encouraging results obtained in experiments with cellular and animal models (described in this review in particular sections presenting various ways of autophagy stimulation), specific treatments of metabolic brain diseases are not yet available. One of the most important problem is appearance of severe adverse effects when strong autophagy stimulators are tested. Such effects were observed for rapamycin, nimodipine, loperamide, niguldipine, nicardipine, panitrem A, fluspirilene, calpastatin, and carbamazepine. Therefore, a compound which activates this process but is also safe in the long-term use is highly desirable. In this light it is worth mentioning that genistein (5, 7-dihydroxy-3- (4-hydroxyphenyl)-4*H*-1-benzopyran-4-one), a natural isoflavone, has been demonstrated recently to decrease levels of mutant huntingtin and to reduce number and size of aggregates of this toxic protein in the cellular model of HD by autophagy stimulation (Pierzynowska et al. [@CR101]). This isoflavone could alleviate lysosomal storage of glycosaminoglycans in vitro and in vivo (in visceral organs and in the brain), and correct animal behavior in various models of mucopolysaccharidosis type I, II and III, a neurodegenerative metabolic disease (Piotrowska et al. [@CR102]; Friso et al. [@CR21]; Malinowska et al. [@CR75], [@CR76]). Genistien has been demonstrated to be safe for a long-term use (over 1 year) at the dose as high as 150 mg/kg/day (Kim et al. [@CR53]). Therefore, it may be considered as a promising agent for development of an effective and safe therapeutics for treatment of neurodegenerative diseases by stimulation of autophagy.

Interestingly, one compound is sometimes able to activate the autophagy process by both mTOR-dependent and mTOR-independent pathways. Such molecules (exemplified by L-NG-nitroarginine methyl ester, trehalose, pimozide or trifluoperazine) are often very effective in removing toxic protein aggregates from cells. It is worth noting that there are links between different mTOR-dependent pathways, which may enhance effects of certain activators of autophagy. Although no such links were discovered between mTOR-dependent and mTOR-independent pathways, the existence of compounds that stimulate autophagy by both these mechanisms might suggest a possibility that there are some cross-talks between molecules involved in both types of pathways.
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